Edgar Filing: Bio-Matrix Scientific Group, Inc.

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

Quarterly Report under Section 13 or 15 (d) of

Securities Exchange Act of 1934

For Period ended March 31, 2014

Commission File Number 0-32201

BIO-MATRIX SCIENTIFIC GROUP, INC.

(Exact name of registrant as specified in its charter)


DELAWARE	33-0824714
(State of Incorporation)	(I.R.S. Employer Identification No.)

4700 Spring Street, Suite 304, La Mesa, California	91942
(Address of Principal Executive Offices)	(Zip Code)

(619) 702-1404

(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☑ No ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☑ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer,” “non-accelerated filer,” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

☐ Large accelerated filer	☐ Accelerated filer
☐ Non-accelerated filer	☑ Smaller reporting company

Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Securities Exchange Act of 1934) (check one): Yes ☑ No ☐

There were 2,951,045,145 shares of Common Stock outstanding as of March 31, 2014.

PART I - FINANCIAL INFORMATION

Item 1. - Financial Statements

BIOMATRIX SCIENTIFIC GROUP, INC.
(A Development Stage Company)
CONSOLIDATED BALANCE SHEET

		As of March 31	As of September 30
		2014	2013
		(unaudited)
	ASSETS
CURRENT ASSETS
	Cash	122,789	116,714
	Prepaid Expenses	15,000	15,000
	Total Current Assets	137,789	131,714


OTHER ASSETS
	Deposits	4,200	4,200
	Deferred Financing Costs	65,000	65,000
	Investment in Subsidiary
	Available for Sale Securities	11,000	7,000
	Total Other Assets	80,200	76,200

TOTAL ASSETS		217,989	207,914

	LIABILITIES AND STOCKHOLDERS' EQUITY

CURRENT LIABILITIES
	Accounts Payable	143,571	138,572
	Notes Payable	371,637	219,372
	Bank Overdraft	801
	Accrued Payroll	502,094	612,094
	Accrued Payroll Taxes	49,338	45,386
	Accrued Interest	253,766	239,829
	Accrued Expenses	5,000	5,000
	Convertible Note Payable Net of Unamortized Discount	97,701	98,701
	Due to Affiliate	6,778	34,895
	Current portion, note payable to affiliated party	1,000	1,000
	Total Current Liabilities	1,431,686	1,394,849

	Total Liabilities	1,431,686	1,394,849

STOCKHOLDERS' EQUITY (DEFICIT)

	Preferred Stock ($.0001 par value) 20,000,000 shares authorized;
	20,000,000 shares authorized; 2063821 issues and outstanding as of
	September 30 2013 and March 31, 2014	207	207
	Series AA Preferred ($0.0001 par value) 100,000 shares authorized
	94,852 issued and outstanding as of September 30, 2013 and
	March 31, 2014	9	9
	Series AAA Preferred ($0.0001 par value) 1,000,000 shares authorized
	40,000 shares issued and outstanding as of September 30, 2013 and March 31, 2014	4	4
	Series B Preferred Shares ($.0001 par value) 2,000,000 shares authorized;
	725,409 issued and outstanding as of September 30, 2013 and
	March 31 , 2014 respectively	73	73
	Common Stock ($.0001 par value) 5,000,000,000 shares authorized;
	2,390,304, 145 and 2,951,045,145 issued and outstanding as of
	September 30, 2013 and March 31 , 2014 respectively	295,099	239,029
	Non Voting Convertible Preferred Stock ($1 Par value)
	200,000 shares authorized; 0 shares issued and outstanding
	as of September 30, 2013 and March 31, 2014
	Additional Paid in capital	16,120,020	14,845,671
	Contributed Capital	509,355	509,355
	Retained Earnings (Deficit) accumulated during the development stage	23,091,871	24,542,314
	Accumulated Other Comprehensive Income (Loss)	(41,325,361)	(41,329,361)
	Total Stockholders' Equity (Deficit) Biomatrix Scientific Group, Inc.	(1,308,723)	(1,192,699)
	Noncontrolling Interest in subsidiary	95,026	5,765
	Total Stockholders' Equity	(1,213,697)	(1,186,934)
TOTAL LIABILITIES & STOCKHOLDERS' EQUITY (DEFICIT)		217,989	207,914

	The Accompanying Notes are an Integral Part of These Financial Statements

BIO MATRIX SCIENTIFIC GROUP,INC
(A Development Stage Company)
CONSOLIDATED STATEMENT OF OPERATIONS


		(unaudited)	(unaudited)	(unaudited)	(unaudited)	(unaudited)
		3 months ended	3 months ended	6 months ended	6 months ended	From inception through
		3/31/14	3/31/13	3/31/14	3/31/13	3/31/14


REVENUES		$ -	$ -	$ -	$ -	$ -

COST AND EXPENSES
	Research and Development	8,042		13,867	6,509	1,296,262
	General and Administrative	139,251	800,531	326,436	973,648	8,543,377
	Depreciation and Amortization					2,668
	Consulting and Professional Fees	37,509	15,671	108,003	71,319	5,332,424
	Impairment of Goodwill and Intangibles					34,688
	Total Costs and Expenses	184,802	816,202	448,306	1,051,476	15,209,419

OPERATING LOSS		(184,802)	(816,202)	(448,306)	(1,051,476)	(15,209,419)

OTHER INCOME & (EXPENSES)
	Interest Expense	(8,523)	(9,965)	(17,407)	(19,918)	(477,573)
	Loss on Early Extinguishment of Debt					(41,688)
	Loss on Settlement of Debt through Equity Issuance	(336,230)		(984,730)		(984,730)
	Interest Expense attributable to amortization of discount		(115,321)		(431,537)	(829,709)
	Interest Income					306
	Securities issued pursuant to contractual obligations				(35,223)	(101,595)
	Other Income					236,916
	Gain on de-consolidation of subsidiary					41,645,688
	Loss on sale of Available for Sale Securities					(487,900)
	Loss on disposal of Equipment					(531,571)
	Other Expense					(166)
Total Other Income & (Expense)		(344,753)	(125,286)	(1,002,137)	(486,678)	38,427,978

NET INCOME (LOSS) before loss attributable to noncontrolling interest in Entest Biomedical, Inc. and equity in subsidiary losses		(529,555)	(941,488)	(1,450,443)	(1,538,154)	23,218,559

(Net Income) Loss attributable to noncontrolling interest in Entest Biomedical, Inc.						536961
	NET INCOME (LOSS) before equity in subsidiary losses	(529,555)	(941,488)	(1,450,443)	(1,538,154)	23,755,520
	Equity in Net Income (Loss) of Entest					(663,649)


NET INCOME (LOSS)		(529,555)	(941,488)	(1,450,443)	(1,538,154)	23,091,871
	Less: (Net Income) Loss attributable to noncontrolling interest Regen Biopharma, Inc.	71,738		78,539		87,372

NET INCOME (LOSS) available to common shareholders		(457,817)	(941,488)	(1,371,904)	(1,538,154)	23,179,243


	BASIC AND FULLY DILUTED EARNINGS (LOSS)	$ (0.0002)	$ (0.0008)	$ (0.0005)	$ (0.0018)
	Weighted average number of shares outstanding	2,916,286,718	1,136,084,829	2,737,817,974	838,129,516

The Accompanying Notes are an Integral Part of These Financial Statements

BIO-MATRIX SCIENTIFIC GROUP, INC.
	(A Development Stage Company)
CONSOLIDATED STATEMENT OF CASH FLOWS




		(unaudited)	(unaudited)	(unaudited)
		Six Months Ended	Six Months Ended	From inception
		March 31, 2014	March 31, 2013	to March 31, 2014

CASH FLOWS FROM OPERATING ACTIVITIES

Net Income (loss)		(1,450,443)	$ (1,538,154)	$ 23,091,871
Adjustments to reconcile net Income to net cash
	(used in) provided by operating activities:
	Depreciation expense			2,667
	Stock issued for compensation to employees		26,400	1,289,551
	Stock issued for services rendered by consultants	380		4,250,070
	Stock issued for prepaid expenses			313,665
	Stock issued for interest	3,570	4,640	147,152
	Stock issued for expenses	48,000	640,000	688,000
	Gain Recognized on Deconsolidation of subsidary			$ (42,000,000)

Changes in operating assets and liabilities:
	(Increase) decrease in prepaid expenses			(15,000)
	Increase (Decrease) in Accounts Payable	4,999	14,805	143,572
	Increase (Decrease) in Accrued Expenses	(92,111)	254,510	840,134
	Increase (Decrease) in bank Overdraft	801	2,286	801
	(Increase) Decrease in Employee Receivable
	Increase (Decrease) in Due to Affiliate	(28,117)	(4,245)	6,778
	Loss attributable to Non Controlling interest in subsidiary
	Equity in Loss of Entest			663,649
	(Increase) Decrease in Gain on cancellation of stock			(25,000)


	Net Cash Provided by (Used in) Operating Activities	(1,512,921)	(599,758)	$ (10,602,090)

CASH FLOWS FROM INVESTING ACTIVITIES
	(Increase) Decrease in Other Assets			(4,200)
	Purchases of fixed assets			(541,536)
	Disposal of Fixed Assets			7,300
	Loss on Disposal of Equipment			531,569
	Net Cash Provided by (Used in) Investing Activities			(6,867)

CASH FLOWS FROM FINANCING ACTIVITIES
	Preferred Stock issued for Cash			874,985
	Common Stock issued for cash			621,164
	Common Stock issued for Accrued Salaries			540,952
	Preferred Stock issued for Accrued Salaries			10,000
	Common Stock issued pursuant to Contractual Obligations		35,223	101,595
	Additional paid in Capital	300,000	390,000	1,652,945
	Principal borrowings on Convertible Debentures		431,537	1,261,179
	Principal borrowings (repayments) on notes and
	Convertible Debentures	234,266	(322,070)	3,043,647
	Net Borrowings From Related Parties			1,195,196
	Contributed Capital			509,353
	Net Borrowings From Related Parties
	Increase (Decrease) in Notes from Affiliated party			1,000
	(Increase) Decrease in Deferred Financing Costs			(65,000)
	Loss on Settlement of Debt through Equity Issuance	984,730		984,730

	Net Cash Provided by (Used in) Financing Activities	1,518,996	534,690	10,731,746

Net Increase (Decrease) in Cash		6,075	(65,068)	$ 122,789

Cash at Beginning of Period		116,714	75,752	0

Cash at End of Period		122,789	$ 10,684	$ 122,789

	Supplemental Disclosure of Noncash investing and financing activities:
	Common Shares Issued for Debt	83,000	$ 379,179	$2,924,289
	Common Shares Issued for Nonvoting Preferred			$75,000

	The Accompanying Notes are an Integral Part of These Financial Statements

BIO-MATRIX SCIENTIFIC GROUP, INC.
(A Development Stage Company)
CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME
(unaudited)

		Quarter ended	Quarter ended
		March 31, 2014	March 31, 2013

	Net Income	(529,555)	(941,488)
	Add:
	Unrealized Gains
	on Securities	8,000	24,000
	Less:
	Unrealized Losses
	on Securities
	Total Other Comprehensive Income (Loss)	8,000	24,000
	Comprehensive Income	(521,555)	(917,488)


		Six Months ended	Six Months ended
		March 31, 2014	March 31, 2013

	Net Income	(1,450,433)	(1,538,154)
	Add:
	Unrealized Gains
	on Securities	4,000	13,000
	Less:
	Unrealized Losses
	on Securities
	Total Other Comprehensive Income (Loss)	4,000	13,000
	Comprehensive Income	(1,446,433)	(1,525,154)

	The Accompanying Notes are an Integral Part of These Financial Statements

The interim financial statements included herein, presented in accordance with United States generally accepted accounting principles and stated in US dollars, have been prepared by Bio-Matrix Scientific Group Inc. (“the Company”), without audit, pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted pursuant to such rules and regulations, although the Company believes that the disclosures are adequate to make the information presented not misleading.

These statements reflect all adjustments, consisting of normal recurring adjustments, which, in the opinion of management, are necessary for fair presentation of the information contained therein. It is suggested that these condensed consolidated interim financial statements be read in conjunction with the financial statements of the Company for the period ended September 30, 2013 and notes thereto included in the Company's 10-K annual report. The Company follows the same accounting policies in the preparation of interim reports.

NOTE 1. ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Bio-Matrix Scientific Group, Inc. (“Company”) was organized October 6, 1998, under the laws of the State of Delaware as Tasco International, Inc.

From October 6, 1998 to June 3, 2006 its activities have been limited to capital formation, organization, and development of its business plan to provide production of visual content and other digital media, including still media, 360-degree images, video, animation and audio for the Internet.

On July 3, 2006 the Company abandoned its efforts in the field of digital media production when it acquired 100% of the share capital of Bio-Matrix Scientific Group, Inc., a Nevada corporation, (“BMSG”) for consideration consisting of 10,000,000 shares of the common stock of the Company and the cancellation of 10,000,000 shares of the Company owned and held by John Lauring.

As a result of this transaction, the former stockholder of BMSG held approximately 80% of the voting capital stock of the Company immediately after the transaction. For financial accounting purposes, this acquisition was a reverse acquisition of the Company by BMSG under the purchase method of accounting, and was treated as a recapitalization with BMSG as the acquirer. Accordingly, the financial statements have been prepared to give retroactive effect to August 2, 2005 (date of inception), of the reverse acquisition completed on July 3, 2006, and represent the operations of BMSG.

Through its 58% owned subsidiary, Regen BioPharma, Inc., the Company intends to engage primarily in the development of regenerative medical applications which we intend to license from other entities up to the point of successful completion of Phase I and or Phase II clinical trials after which we would either attempt to sell or license those developed applications or, alternatively, advance the application further to Phase III clinical trials

A. BASIS OF ACCOUNTING

The financial statements have been prepared using the basis of accounting generally accepted in the United States of America. Under this basis of accounting, revenues are recorded as earned and expenses are recorded at the time liabilities are incurred. The Company has adopted a September 30 year-end.

B. PRINCIPLES OF CONSOLIDATION

The consolidated financial statements include the accounts of Bio-Matrix Scientific Group, inc., a Delaware corporation, Bio Matrix Scientific Group, Inc, a Nevada corporation and a wholly owned subsidiary (“BMSG”), Regen BioPharma, Inc., a Nevada corporation and 58% owned subsidiary (Regen) and Entest BioMedical, Inc., (“Entest”), a Nevada corporation which was a majority owned subsidiary up to February 3, 2011. Significant inter-company transactions have been eliminated.

C. USE OF ESTIMATES

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. All estimates are of a normal, recurring nature and are required for the fair presentation of the financial statements. Actual results could differ from those estimates.

D. DEVELOPMENT STAGE

The Company is a development stage company devoting substantially all of its efforts to establish a new business.

E. CASH EQUIVALENTS

The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents.

F. PROPERTY AND EQUIPMENT

Property and equipment are recorded at cost. Maintenance and repairs are expensed in the year in which they are incurred. Expenditures that enhance the value of property and equipment are capitalized.

G. FAIR VALUE OF FINANCIAL INSTRUMENTS

Fair value is the price that would be received for an asset or the exit price that would be paid to transfer a liability in the principal or most advantageous market in an orderly transaction between market participants on the measurement date. A fair value hierarchy requires an entity to maximize the use of observable inputs, where available. The following summarizes the three levels of inputs required by the standard that the Company uses to measure fair value:

Level 1: Quoted prices in active markets for identical assets or liabilities

Level 2: Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities.

Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

The Company’s financial instruments as of March 31, 2014 consisted of Securities Available for Sale consisting of 10,000,000 shares of Entest Biomedical, Inc. The fair value of all of the Company’s financial instruments as of March 31, 2014 were valued according to the Level 1 input. The carrying amount of the financial instruments is equal to the fair value as determined by the Company

H. INCOME TAXES

The Company accounts for income taxes using the liability method prescribed by ASC 740, “Income Taxes.” Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates that will be in effect in the year in which the differences are expected to reverse. The Company records a valuation allowance to offset deferred tax assets if based on the weight of available evidence, it is more-likely-than-not that some portion, or all, of the deferred tax assets will not be realized. The effect on deferred taxes of a change in tax rates is recognized as income or loss in the period that includes the enactment date.

The Company applied the provisions of ASC 740-10-50, “Accounting For Uncertainty In Income Taxes”, which provides clarification related to the process associated with accounting for uncertain tax positions recognized in our financial statements. Audit periods remain open for review until the statute of limitations has passed. The completion of review or the expiration of the statute of limitations for a given audit period could result in an adjustment to the Company’s liability for income taxes. Any such adjustment could be material to the Company’s results of operations for any given quarterly or annual period based, in part, upon the results of operations for the given period. As of March 31, 2014 the Company had no uncertain tax positions, and will continue to evaluate for uncertain positions in the future.

The Company generated a deferred tax credit through net operating loss carry forward. However, a valuation allowance of 100% has been established.

Interest and penalties on tax deficiencies recognized in accordance with ACS accounting standards are classified as income taxes in accordance with ASC Topic 740-10-50-19.

I. BASIC EARNINGS (LOSS) PER SHARE

The Financial Accounting Standards Board (FASB) issued Accounting Standards Codification (ASC) 260, "Earnings Per Share", which specifies the computation, presentation and disclosure requirements for earnings (loss) per share for entities with publicly held common stock. ASC 260 requires the presentation of basic earnings (loss) per share and diluted earnings (loss) per share. The Company has adopted the provisions of ASC 260 effective from inception.

Basic net loss per share amounts is computed by dividing the net income by the weighted average number of common shares outstanding. All options and convertible debt outstanding has an anti-dilutive effect on the EPS, therefore Diluted Earnings per Share are the same as basic earnings per share.

J. ADVERTISING

Costs associated with advertising are charged to expense as incurred. Advertising expenses were $0 and $0 for the year ended September 30, 2013 and the quarter ended March 31, 2014 respectively.

NOTE 2. RECENT ACCOUNTING PRONOUNCEMENTS

The following accounting standards updates were recently issued and have not yet been adopted by us. These standards are currently under review to determine their impact on our consolidated financial position, results of operations, or cash flows.

On January 31, 2013, the FASB issued Accounting Standards Update [ASU] 2013-01, entitled Clarifying the Scope of Disclosures about Offsetting Assets and Liabilities. The guidance in ASU 2013-01 amends the requirements in the FASB Accounting Standards Codification [FASB ASC] Topic 210, entitled Balance Sheet. The ASU 2013-01 amendments to FASB ASC 210 clarify that ordinary trade receivables and receivables in general are not within the scope of ASU 2011-11, entitled Disclosure about Offsetting Assets and Liabilities, where that ASU amended the guidance in FASB ASC 210. As those disclosures now are modified with the ASU 2013-01 amendments, the FASB ASC 210 balance sheet offsetting disclosures now clearly are applicable only where reporting entities are involved with bifurcated embedded derivatives, repurchase agreements, reverse repurchase agreements, and securities borrowing and lending transactions that either are offset using the FASB ASC 210 or 815 requirements, or that are subject to enforceable master netting arrangements or similar agreements. ASU 2013-01 is effective for annual reporting periods beginning on or after January 1, 2013, and interim periods within those annual periods. The adoption of this ASU is not expected to have a material impact on our financial statements.

On February 28, 2013, the FASB issued Accounting Standards Update [ASU] 2013-04, entitled Obligations Resulting from Joint and Several Liability Arrangements for Which the Total Amount of the Obligation Is Fixed at the Reporting Date. The ASU 2013-04 amendments add to the guidance in FASB Accounting Standards Codification [FASB ASC] Topic 405, entitled Liabilities and require reporting entities to measure obligations resulting from certain joint and several liability arrangements where the total amount of the obligation is fixed as of the reporting date, as the sum of the following:

The amount the reporting entity agreed to pay on the basis of its arrangement among co-obligors.

Any additional amounts the reporting entity expects to pay on behalf of its co-obligors.

While early adoption of the amended guidance is permitted, for public companies, the guidance is required to be implemented in fiscal years, and interim periods within those years, beginning after December 15, 2013. The amendments need to be implemented retrospectively to all prior periods presented for obligations resulting from joint and several liability arrangements that exist at the beginning of the year of adoption. The adoption of ASU 2013-04 is not expected to have a material effect on the Company’s operating results or financial position.

On April 22, 2013, the FASB issued Accounting Standards Update [ASU] 2013-07, entitled Liquidation Basis of Accounting. With ASU 2013-07, the FASB amends the guidance in the FASB Accounting Standards Codification [FASB ASC] Topic 205, entitled Presentation of Financial Statements. The amendments serve to clarify when and how reporting entities should apply the liquidation basis of accounting. The guidance is applicable to all reporting entities, whether they are public or private companies or not-for-profit entities. The guidance also provides principles for the recognition of assets and liabilities and disclosures, as well as related financial statement presentation requirements. The requirements in ASU 2013-07 are effective for annual reporting periods beginning after December 15, 2013, and interim reporting periods within those annual periods. Reporting entities are required to apply the requirements in ASU 2013-07 prospectively from the day that liquidation becomes imminent. Early adoption is permitted. The adoption of ASU 2013-07 is not expected to have a material effect on the Company’s operating results or financial position.

Variety of proposed or otherwise potential accounting standards are currently under study by standard setting organizations and various regulatory agencies. Due to the tentative and preliminary nature of those proposed standards, the Company’s management has not determined whether implementation of such standards would be material to its financial statements.

NOTE 3. OPTIONS AND WARRANTS

As of March 31, 2014 the Company has no options or warrants outstanding.

NOTE 4. GOING CONCERN

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. Exclusive of a onetime non-cash gain of $41,645,688 recognized upon the deconsolidation of Entest Biomedical, Inc., the Company generated net losses of $17,890,169 (excluding $663,649 of Equity in Net Losses of Entest Biomedical, Inc. recognized) during the period from August 2, 2005 (inception) through March 31, 2014. This condition raises substantial doubt about the Company's ability to continue as a going concern. The Company's continuation as a going concern is dependent on its ability to meet its obligations, to obtain additional financing as may be required and ultimately to attain profitability. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Management plans to raise additional funds by offering securities for cash.

On April 26, 2012 the Company executed an Equity Purchase Agreement (the "Purchase Agreement") and Registration Rights Agreement (the "Rights Agreement") with Southridge Partners II, LP, and a Delaware limited partnership ("Southridge").

Under the terms of the Purchase Agreement, Southridge will purchase, at the Company's election, up to $20,000,000 of the Company's registered common stock (the "Shares"). During the term of the Purchase Agreement, the Company may at any time deliver a "put notice" to Southridge thereby requiring Southridge to purchase a certain dollar amount of the Shares. Simultaneous with the delivery of such Shares, Southridge shall deliver payment for the Shares. Subject to certain restrictions, the purchase price for the Shares shall be equal to 91% of the Market Price, as such capitalized term is defined in the Purchase Agreement, on such date on which the Purchase Price is calculated in accordance with the terms and conditions of this Agreement.

Market Price, as such term is defined in the Purchase Agreement, means the lowest Closing Price, as such term is defined in the Purchase Agreement, during the Valuation Period, and as such term is defined in the Purchase Agreement.

Closing Price is defined in the Purchase Agreement as the closing bid price for the Company’s common stock on the principal market over which the Company’s common shares trade on a day on which that principal market is open for business as reported by Bloomberg Finance L.P.

Valuation Period , as such term is defined in the Purchase Agreement, means the period of 5 Trading Days immediately following the Clearing Date, as such term is defined in the Purchase Agreement, associated with the applicable Put Notice during which the Purchase Price of the Shares is valued.

Clearing Date, as such term is defined in the Purchase Agreement, means the date in which the Estimated Put Shares (as defined in Section 2.2(a) of the Purchase Agreement) have been deposited into Southridge’s brokerage account and Southridge’s broker has confirmed with Southridge that Southridge may execute trades of such Estimated Put Shares.

The definition of Estimated Put Shares in Section 2.2(a) of the Purchase Agreement is that number of Shares equal to the dollar amount indicated in the Put Notice divided by the Closing Price on the Trading Day immediately preceding the Put Date, multiplied by 125%. Pursuant to the Purchase Agreement, on a Put Date the Company will be required to the applicable number of Estimated Put Shares to Southridge’s brokerage account. At the end of the Valuation Period the Purchase Price shall be established and the number of Shares shall be determined for a particular Put. If the number of Estimated Put Shares initially delivered to Southridge is greater than the Put Shares purchased by Southridge pursuant to such Put, then immediately after the Valuation Period Southridge shall deliver to Company any excess Estimated Put Shares associated with such Put. If the number of Estimated Put Shares delivered to Investor is less than the Shares purchased by Southridge pursuant to a Put, then immediately after the Valuation Period the Company shall deliver to Southridge the difference between the Estimated Put Shares and the Shares issuable pursuant to such Put.

The number of Shares sold to Southridge shall not exceed the number of such shares that, when aggregated with all other shares of common stock of the Company then beneficially owned by Southridge, would result in Southridge owning more than 9.99% of all of the Company's common stock then outstanding. Additionally, Southridge may not execute any short sales of the Company's common stock.

The Purchase Agreement shall terminate (i) on the date on which Southridge shall have purchased Shares pursuant to this Agreement for an aggregate Purchase Price of $20,000,000, or (ii) on the date occurring 24 months from the date on which the Agreement was executed and delivered by the Company and Southridge.

Under the terms of the Rights Agreement, the Company agreed to file a registration statement with the Securities and Exchange Commission within 90 days of the date on which the Purchase Agreement was executed and delivered by the Company and Southridge.

The registration statement shall be filed with respect to not less than the maximum allowable number of Shares issuable pursuant to a put notice to Southridge that has been exercised or may be exercised in accordance with the terms and conditions of the Purchase Agreement permissible under Rule 415, promulgated under the Securities Act of 1933.

The Company is obligated to keep such registration statement effective until (i) three months after the last closing of a sale of Shares under the Purchase Agreement, (ii) the date when Southridge may sell all the Shares under Rule 144 without volume limitations, or (iii) the date Southridge no longer owns any of the Shares.

The Purchase Agreement requires the Company to reserve and keep available until the consummation of such Closing, free of preemptive rights sufficient shares of common stock for the purpose of enabling the Company to satisfy its obligation to issue the Shares.

The Purchase Agreement also requires the Company to issue to Southridge shares of a newly designated preferred stock with a stated value of $50,000 convertible at the option of Southridge into shares of the Company’s common stock at a conversion price equal to seventy percent (70%) of the lowest Closing Price for the five (5) trading days immediately preceding a conversion notice. The Preferred Stock shall have no registration rights.

During the quarter ended March 31, 2014 Regen the Company incurred net borrowings of $17,700 such funds being borrowed from David Koos, the Company’s Chairman and Chief Executive Officer .

NOTE 5. INCOME TAXES

As of March 31, 2014

Deferred tax assets:
Net operating tax carry forwards	$	6,095,786
Other		-0-
Gross deferred tax assets		6,095,786
Valuation allowance		(6,095,786	)

Net deferred tax assets	$	-0-

As of March 31, 2014 the Company has a Deferred Tax Asset of $6,095,786 completely attributable to net operating loss carry forwards of approximately $17,928,785 ( which expire 20 years from the date the loss was incurred) consisting of

(a) $38,616, of Net Operating Loss Carry forwards acquired in the reverse acquisition of BMSG and

(b) $17,890,168 attributable to Bio-Matrix Scientific Group, Inc. a Delaware corporation, BMSG and Regen.

Realization of deferred tax assets is dependent upon sufficient future taxable income during the period that deductible temporary differences and carry forwards are expected to be available to reduce taxable income. The achievement of required future taxable income is uncertain. In addition, the reverse acquisition of BMSG has resulted in a change of control. Internal Revenue Code Sec 382 limits the amount of income that may be offset by net operating loss (NOL) carryovers after an ownership change. As a result, the Company has the Company recorded a valuation allowance reducing all deferred tax assets to 0.

Income tax is calculated at the 34% Federal Corporate Rate.

NOTE 6. RELATED PARTY TRANSACTIONS

As of March 31, 2014 the Company is indebted to David Koos, the Company’s Chairman and Chief Executive Officer, in the amount of $171,637. These loans and any accrued interest are due and payable at the demand of Mr. Koos and bear simple interest at the rate of 15% per annum.

On June 15, 2009 Entest entered into an agreement with the Company whereby Entest has agreed to sublease approximately 3,000 square feet of office space from the Company for a term of 3 years for consideration consisting of monthly rental payments of $4,100 per month. Beginning October 2010 Entest has been paying rental expenses directly to the owner of the subleased space leaving a balance of $59,500 of rental expenses prepaid to the Company as of that date. As of March 31, 2014 the amount due to Entest is $6,778. This obligation bears no interest and is due and payable on the demand of Entest. Entest is considered a related party due to the fact that the Chairman and CEO of the Company also serves as the Chairman and CEO of Entest.

NOTE 7. NOTES PAYABLE

	March 31, 2014		September 30, 2013

Dunhill Ross Partners, Inc. ( formerly Venture Bridge Advisors)		0		82,000
The Sherman Family Trust		200,000
David Koos (Note 6)		171,637		137,372
Notes payable	$	371,637	$	219,372

Dunhill Ross Partners, Inc. has provided a line of credit to the Company in the amount of $700,000 or so much thereof as may be disbursed to, or for the benefit of the Company by Lender in Lender's sole and absolute discretion. The unpaid principal of this line of credit bears simple interest at the rate of ten percent per annum. Interest is calculated based on the principal balance as may be adjusted from time to time to reflect additional advances or payments made hereunder. Principal balance and accrued interest shall become due and payable in whole or in part at the demand of the Lender.

All loans to the Company made by David R. Koos are due and payable at the demand of Koos and bear simple interest at a rate of 15% per annum.

All amounts due to the Sherman Family Trust bear no interest and are due and payable, in whole or in part, at the option of the holder.

NOTE 8. STOCKHOLDERS' EQUITY

The stockholders' equity section of the Company contains the following classes of capital stock as of March 31, 2014:

Preferred stock, $0.0001 par value; 20,000,000 shares authorized:

2,063,821 Preferred Shares, par value $0.0001, issued and outstanding.

With respect to each matter submitted to a vote of stockholders of the Corporation, each holder of Preferred Stock shall be entitled to cast that number of votes which is equivalent to the number of shares of Series B Preferred Stock owned by such holder times one (1).

On any voluntary or involuntary liquidation, dissolution or winding up of the Corporation, the holders of the Preferred Stock shall receive, out of assets legally available for distribution to the Company's stockholders, a ratable share in the assets of the Corporation.

94,852 Series AA Preferred Shares, par value $0.0001, issued and outstanding.

With respect to each matter submitted to a vote of stockholders of the Corporation, each holder of Series AA Preferred Stock shall be entitled to cast that number of votes which is equivalent to the number of shares of Series AA Preferred Stock owned by such holder times ten thousand (10,0000).

On any voluntary or involuntary liquidation, dissolution or winding up of the Corporation, the holders of the Series AA Preferred Stock shall receive, out of assets legally available for distribution to the Company's stockholders, a ratable share in the assets of the Corporation.

40,000 Series AAA Preferred Shares, par value $0.0001, issued and outstanding.

725,409 Series B Preferred Shares, Par Value $0.0001, issued and outstanding.

With respect to each matter submitted to a vote of stockholders of the Corporation, each holder of Series B Preferred Stock shall be entitled to cast that number of votes which is equivalent to the number of shares of Series B Preferred Stock owned by such holder times two (2).

On any voluntary or involuntary liquidation, dissolution or winding up of the Corporation, the holders of the Series B Preferred Stock shall receive, out of assets legally available for distribution to the Company's stockholders, a ratable share in the assets of the Corporation.

Non Voting Convertible Preferred Stock, $1.00 Par value, 200,000 shares authorized, 0 shares issued and outstanding

Each Non Voting Convertible Preferred Stock shall convert at the option of the holder into shares of the corporation’s common stock at a conversion price equal to seventy percent (70%) of the lowest Closing Price for the five (5) trading days immediately preceding written receipt by the corporation of the holder’s intent to convert.

“CLOSING PRICE" shall mean the closing bid price for the corporation’s common stock on the Principal Market on a Trading Day as reported by Bloomberg Finance L.P.

“PRINCIPAL MARKET" shall mean the principal trading exchange or market for the corporation’s common stock.

“TRADING DAY” shall mean a day on which the Principal Market shall be open for business.

On any voluntary or involuntary liquidation, dissolution or winding up of the Corporation, the holders of the Non Voting Convertible Preferred shall receive, out of assets legally available for distribution to the Company's stockholders, a ratable share in the assets of the Corporation.

Common stock, $ 0.0001 par value; 5,000,000,000 shares authorized: 2,951,045,145 shares issued and outstanding.

With respect to each matter submitted to a vote of stockholders of the Corporation, each holder of Common Stock shall be entitled to cast that number of votes which is equivalent to the number of shares of Common Stock owned by such holder times one (1).

On any voluntary or involuntary liquidation, dissolution or winding up of the Corporation, the holders of the Common Stock shall receive, out of assets legally available for distribution to the Company's stockholders, a ratable share in the assets of the Corporation.

NOTE 9. CONVERTIBLE DEBENTURES

At March 31, 2014, the following convertible debentures remain outstanding:

(a) $80,701 in aggregate convertible debt bearing simple interest at 12% per annum convertible into the Company’s common stock at $0.025 per share.

(b) $17,000 in aggregate convertible debt bearing no interest convertible into the Company’s common stock at share and convertible into common shares of the Company at a conversion price per share equal to 55% (the “Discount”) of the lowest closing bid price for the Company’s common stock during the five trading days immediately preceding a conversion date, as reported by Bloomberg.

Convertible Debentures described in (a) and (b) are currently due and payable. The holders have not made a demand for payment

As of March 31, 2014 the Aggregate Amount of Convertible Debentures outstanding was $97,701 and the Aggregate Amount of Unamortized discount was $0.

NOTE 10. COMMITMENTS AND CONTINGENCIES

On April 12, 2013 a complaint (Complaint) was filed in the U.S. District Court Southern District of the State of new York against the Company, the Company’s Chairman and Does 1-50 by Star city Capital, LLC (“Plaintiff”) alleging securities fraud, common law fraud, negligent misrepresentation, breach of fiduciary duties and breach of contract in connection with the issuance of . The Plaintiff is also request declaratory relief from the Court.

The action arises from the issuance and subsequent cancellation of 103,030,303 of the company’s common shares in satisfaction of $17,000 of convertible indebtedness of the Company held by the Plaintiff. The Plaintiff alleges that a cancellation notice sent by them to the Company’s transfer agent was meant to instruct the Transfer Agent simply to cancel the physical certificate in order that an equivalent number of shares may be transferred via DWAC to the Plaintiff’s stockbroker for the benefit of the Plaintiff. DWAC is the acronym for Deposit/Withdrawal At Custodian. The DWAC transaction system run by The Depository Trust Company (a.k.a. DTC or CEDE & CO) permits brokers and custodial banks, the DTC participants, to request the movement of shares to or from the issuer’s transfer agent electronically. A DWAC results in the crediting or debiting of shares to or from DTC’s book-entry account on the records of the issuer maintained by the transfer agent.

The Company believes that the cancellation notice sent by the Plaintiff clearly represents a cancellation of the conversion notice itself.

The convertible indebtedness held by the Plaintiff is convertible at Holder’s demand into the common shares of the Company’s stock at a conversion price per share equal to 55% (the “Discount”) of the lowest closing bid price for the Company’s common stock during the 5 trading days immediately preceding a conversion date, as reported by Bloomberg (the “Closing Bid Price”); provided that if the closing bid price for the common stock on the date in which the conversion shares are deposited into Holder’s brokerage account and confirmation has been received that Holder may execute trades of the conversion shares ( Clearing Date) is lower than the Closing Bid Price, then the purchase price for the conversion shares would be adjusted such that the Discount shall be taken from the closing bid price on the Clearing Date, and the Company shall issue additional shares to Purchaser to reflect such adjusted Purchase Price(“Reset”). The Company and the Plaintiff had agreed on a limitation on conversion equal to 9.99% of the Company’s outstanding common stock. There can be no assurance that a subsequent conversion notice for the same amount of indebtedness issued by the Plaintiff would convert into 103,030,303 of the company’s common shares.

On August 21, 2012 the Company entered into a settlement funding agreement with Princeton Research, Inc. and Jan Vandersande (collectively the “PRI Parties”) which obligates the Company to pay the PRI Parties $1,000 a month over thirty months.

NOTE 11. INVESTMENT SECURITIES

As of the quarter ending June 30, 2012 the Company reclassified 10,000,000 common shares of Entest (“Entest Shares”) as Securities Available for Sale from Securities Accounted for under the Equity Method. The Entest Shares are the Company’s sole Investment Securities as of March 31, 2014.

NOTE 12. PROPERTY DIVIDEND

On March 25, 2014 the Company paid a property dividend of 20,000,000 common shares of Regen Biopharma, Inc. to its shareholders. This dividend was distributed pro rata to all common and preferred shareholders of record as of March 18, 2014

NOTE 13. STOCK TRANSACTIONS

On January 23, 2014 the Company Issued 140,000,000 Common Shares in satisfaction of $ 14,070 of indebtedness.

On January 28, 2014 the Company Issued 500,000 Common Shares in satisfaction of $ 1,000 of convertible indebtedness.

Item 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

CERTAIN FORWARD-LOOKING INFORMATION

Information provided in this Quarterly report on Form 10Q may contain forward-looking statements within the meaning of Section 21E or Securities Exchange Act of 1934 that are not historical facts and information. These statements represent the Company's expectations or beliefs, including, but not limited to, statements concerning future and operating results, statements concern industry performance, the Company's operations, economic performance, financial conditions, margins and growth in sales of the Company's products, capital expenditures, financing needs, as well assumptions related to the forgoing. For this purpose, any statements contained in this Quarterly Report that are not statement of historical fact may be deemed to be forward-looking statements. These forward-looking statements are based on current expectations and involve various risks and uncertainties that could cause actual results and outcomes for future periods to differ materially from any forward-looking statement or views expressed herein. The Company's financial performance and the forward-looking statements contained herein are further qualified by other risks including those set forth from time to time in the documents filed by the Company with the Securities and Exchange Commission, including the Company's most recent Form 10Kfor the year ended September 30, 2013. All references to” We”, “Us”, “Company” or the “Company” refer to Bio-Matrix Scientific Group, Inc.

Material Changes in Financial Condition:

As of March 31, 2014 we had Cash on Hand of $122,789 and as of September 30, 2013 we had Cash on Hand of $ 116,714

The increase in Cash on Hand of approximately 5.2 % is primarily attributable to:

(a)

The sale during the quarter ended December 31, 2013 of 300,000 newly issued common shares of Regen Biopharma, Inc. for proceeds of $300,000

(b)

Net loans totaling $16,565 made by David Koos, the Company’s Chairman and Chief Executive Officer, to the Company during the quarter ended December 31, 2013

(c)

Net loans totaling $17,700 made by David Koos, the Company’s Chairman and Chief Executive Officer, to the Company during the quarter ended March 31, 2014

Offset By:

(a)

Payments of $28,117 made to or on behalf of Entest Biomedical, Inc.

(b)

Funds expended in the ordinary course of business.

As of March 31, 2014 we had Available for Sale Securities of $11,000 and as of September 30, 2013 we had Available for Sale Securities of $7,000. The increase in Available for Sale Securities of approximately 57% is primarily attributable to remeasurement based on unrealized gain.

As of March 31, 2014 we had Notes Payable of $ 371,637 and as of September 30, 2013 we had Notes Payable of $ 219,372.

This increase of approximately 69% is primarily attributable to:

(a)

Net Loans of $33, 243 made to the Company by the Company’s Chairman and Chief Executive Officer

(b)

The reclassification of $200,000 of Accrued Salary to Note Payable.

Offset by:

The satisfaction of $82,000 of principal indebtedness through the issuance of the Company’s common stock during the six months ended March 31, 2014..

As of March 31, 2014 we had Accrued Payroll of $502,094 and as of September 30, 2013 we had Accrued Payroll of $ 612,094.

The decrease in Accrued Payroll of approximately 18% is primarily attributable to the reclassification of $200,000 of salaries accrued but unpaid as Notes payable offset by compensation expenses incurred during the six months ended March 31, 2014 with regards to the salaries of David Koos ( our CEO), and Thomas Ichim (who is employed by Regen) which remain unpaid as of March 31, 2014.

As of March 31, 2014 we had Accrued Payroll Taxes of $ 49,338 and as of September 30, 2013 we had Accrued Payroll Taxes $45,386.

This increase of approximately 8% is primarily attributable to the net accrual of $3,952 of payroll taxes payable during the six months ended March 31, 2014.

As of March 31, 2014 we had $ 6,778 in Amount Due to Affiliate and as of September 30, 2013 we had $34,895 in Amount Due to Affiliate. The decrease of approximately 81% is attributable to payments of $28,117 made to or on behalf of Entest Biomedical, Inc. by the Company over the six months ended March 31, 2014.

As of March 31, 2014 we had Accrued Interest of $ 253,766 and as of September 30, 2013 we had Accrued Interest of $239,829.

This increase of approximately 5.8% is primarily attributable to interest on Notes payable and Convertible Notes payable accrued but unpaid over the six months ended March 31, 2014.

Material Changes in Results of Operations

Revenues were -0- for the quarter ending March 31, 2014 and -0- for the same quarter ending 2013. Net Losses were $529,555 for the three months ended March 31, 2014. Net Losses were $941,488 for the same quarter ending 2013 .The decrease in Net Loss of approximately 44% is primarily attributable to:

(a)

Higher general and administrative expenses incurred over the quarter ended March 31, 2013 when compared to the same quarter ended 2014.

(b)

Higher interest expense incurred over the quarter ended March 31, 2013 when compared to the same quarter ended 2014.

(c)

The recognition of $115,321 of Interest Expense Attributable to Amortization of Discount during the quarter ended March 31, 2013.

Offset by:

(a)

Higher Research and Development expenses and Consulting Fees incurred over the quarter ended March 31, 2014 when compared to the same quarter ended 2013.

(b)

The recognition during the quarter ended March 31, 2014 of $336,230 of expenses attributable to the issuance of common stock for less than fair value in satisfaction of indebtedness of the Company

Revenues were -0- for the six months ending March 31, 2014 and -0- for the same period ending 2013. Net Losses were $ 1,450,443 for the six months ended March 31, 2014. Net Losses were $1,538,154 for the same period ending 2013 . The decrease in Net Loss of approximately 5.7 % is primarily attributable to:

(a)

Higher general and administrative expenses incurred over the six months ended March 31, 2013 when compared to the same period ended 2014.

(b)

Higher interest expense incurred over the six months ended March 31, 2013 when compared to the same period ended 2014.

(c)

The recognition of $431,537 of Interest Expense Attributable to Amortization of Discount during the six months ended March 31, 2013.

Offset by:

(a)

Higher Research and Development expenses and Consulting Fees incurred over the six months ended March 31, 2014 when compared to the same period ended 2013.

(b)

The recognition during the six months ended March 31, 2014 of $984,730 of expenses attributable to the issuance of common stock for less than fair value in satisfaction of indebtedness of the Company

Liquidity and Capital Resources

As of March 31, 2014, we had $122,789 cash on hand and current liabilities of $1,431,686 such liabilities consisting primarily of Accounts Payable, Notes Payable, Expenses Accrued but not yet paid, Convertible Notes Payable and Amounts due to Affiliated Parties.

We feel we will not be able to satisfy our cash requirements over the next twelve months and shall be required to seek additional financing.

During the six months ended March 31, 2013 we satisfied our cash requirements primarily through borrowings from David Koos, the Company’s CEO and sale of the common shares of Regen Biopharma, Inc. for cash consideration. There can also be no assurance given by the Company that funds will continue to be lent to the Company by David Koos or that the Company will be successful in selling either its own or its subsidiary’s securities in the future.

The Company plans to meet cash needs through applying for governmental and non-governmental grants as well as selling its securities for cash. Management has yet to decide what type of offering the Company will use or how much capital the Company will raise. There is no guarantee that the Company will be able to raise any capital through any type of offerings. Management can give no assurance that any governmental or non-governmental grant will be obtained by the Company despite the Company’s best efforts. As of February 19, 2014 Regen BioPharma, Inc , a majority owned subsidiary of the Company, has identified the National Heart Lung and Blood Institute Clinical Trial Pilot Studies (R34) grant which provides up to $450,000 in funding over a period of three years as well as the Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications administered by the Small Business Innovation Research (SBIR) program of the National Institute of Health as grants for which the Company intends to apply.

We cannot assure that we will be successful in obtaining additional financing necessary to implement our business plan. We have not received any commitment or expression of interest from any financing source that has given us any assurance that we will obtain the amount of additional financing in the future that we currently anticipate. For these and other reasons, we are not able to assure that we will obtain any additional financing or, if we are successful, that we can obtain any such financing on terms that may be reasonable in light of our current circumstances. We were not party to any material commitments for capital expenditures as of the end of the quarter ended March 31, 2014. Other than what is disclosed in this document, The Company is unaware of any trends, demands or uncertainties that will result in the Company’s liquidity increasing or decreasing in any material way.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

As a smaller reporting company, as defined by Rule 229.10(f) (1) of Regulation S-K, we are not required to provide the information required by this Item. We have chosen to disclose, however, that we have not engaged in any transactions, issued or bought any financial instruments or entered into any contracts that are required to be disclosed in response to this item.

Item 4. Controls and Procedures.

Evaluation of Disclosure Controls and Procedures

As of the end of the period covered by this report, the Company carried out an evaluation, under the supervision and with the participation of David Koos, who is the Company's Principal Executive Officer/Principal Financial Officer, of the effectiveness of the design and operation of the Company's disclosure controls and procedures. The Company's disclosure controls and procedures are designed to provide a reasonable level of assurance of achieving the Company's disclosure control objectives. The Company's Principal Executive Officer/Principal Financial Officer has concluded that the Company's disclosure controls and procedures are, in fact, effective at this reasonable assurance level as of the period covered.

Changes in Internal Controls over Financial Reporting

In connection with the evaluation of the Company's internal controls during the period commencing on January 1, 2014 and ending March 31, 2014, David Koos, who is both the Company's Principal Executive Officer and Principal Financial Officer has determined that there were no changes to the Company's internal controls over financial reporting that have been materially affected, or is reasonably likely to materially effect, the Company's internal controls over financial reporting.

PART II - OTHER INFORMATION

Item 1. Legal Proceedings.

The Company believes that the cancellation notice sent by the Plaintiff clearly represents a cancellation of the conversion notice itself.

Although the Company believes this legal action has no merit, it is not possible to predict the ultimate outcome of this legal action.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

On January 23, 2014 the Company Issued 140,000,000 Common Shares (“Shares’) in satisfaction of $ 14,070 of indebtedness.

The Shares were issued pursuant to Section 4(a) (2) of the Securities Act of 1933, as amended (the “Act”). No underwriters were retained to serve as placement agents for the sale. The shares were sold directly through our management. No commission or other consideration was paid in connection with the sale of the shares. There was no advertisement or general solicitation made in connection with this Offer and Sale of Shares.

On January 28, 2014 the Company Issued 500,000 Common Shares (“Shares”) in satisfaction of $ 1,000 of convertible indebtedness.

Item 3. DEFAULTS UPON SENIOR SECURITIES

None.

Item 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

None.

Item 5. OTHER INFORMATION

None

Item 6. EXHIBITS

31.1	Certification of Chief Executive Officer
31.2	Certification of Acting Chief Financial Officer
32.1	Certification of Chief Executive Officer under Section 906 of the Sarbanes-Oxley Act of 2002.
32.2	Certification of Acting Chief Financial Officer under Section 906 of the Sarbanes-Oxley Act of 2002.

SIGNATURES

In accordance with the requirements of the Exchange Act, Bio-Matrix Scientific Group Inc. caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Bio-Matrix Scientific Group, Inc.

Date: May 9, 2014	By:	/s/ David R. Koos
		David R. Koos Chief Executive Officer